Autopsy report · NCT00818675
A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 3 years 5 months before it stopped.
- 80 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Lead-In Ridaforolimus; Comparator: Blinded Ridaforolimus; Comparator: Blinded Placebo
- Participants
- 80
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.